BE2012C040I2 - - Google Patents

Info

Publication number
BE2012C040I2
BE2012C040I2 BE2012C040C BE2012C040C BE2012C040I2 BE 2012C040 I2 BE2012C040 I2 BE 2012C040I2 BE 2012C040 C BE2012C040 C BE 2012C040C BE 2012C040 C BE2012C040 C BE 2012C040C BE 2012C040 I2 BE2012C040 I2 BE 2012C040I2
Authority
BE
Belgium
Prior art keywords
administering
therapy
prevention
patient
rapid
Prior art date
Application number
BE2012C040C
Other languages
French (fr)
Original Assignee
Apbi Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22542905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2012C040(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apbi Holdings Llc filed Critical Apbi Holdings Llc
Publication of BE2012C040I2 publication Critical patent/BE2012C040I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Methods for the prevention, treatment or management of sexual dysfunction, as premature ejaculation, by administering to a patient in need of therapy a therapeutically effective amount of a rapid-onset selective serotonin reuptake inhibitor on an as-needed basis shortly before sexual activity.
BE2012C040C 1999-09-03 2012-10-11 BE2012C040I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15243599P 1999-09-03 1999-09-03
PCT/US2000/020788 WO2001017521A1 (en) 1999-09-03 2000-08-22 Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
EP00957264A EP1225881B1 (en) 1999-09-03 2000-08-22 The use of dapoxetine, a rapid-onset selective serotonin reuptake inhibitor, for treating sexual dysfunction

Publications (1)

Publication Number Publication Date
BE2012C040I2 true BE2012C040I2 (en) 2019-10-16

Family

ID=22542905

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2012C040C BE2012C040I2 (en) 1999-09-03 2012-10-11

Country Status (34)

Country Link
US (4) US7718705B1 (en)
EP (3) EP1671628B1 (en)
JP (1) JP3194734B2 (en)
KR (1) KR100719977B1 (en)
CN (1) CN1222283C (en)
AT (1) ATE318135T1 (en)
AU (1) AU762934B2 (en)
BE (1) BE2012C040I2 (en)
BG (1) BG65677B1 (en)
BR (1) BR0014166A (en)
CA (1) CA2383785C (en)
CY (1) CY2012028I1 (en)
CZ (1) CZ299712B6 (en)
DE (2) DE60026146T2 (en)
DK (1) DK1225881T3 (en)
EA (1) EA004101B1 (en)
EE (1) EE05315B1 (en)
ES (2) ES2256032T3 (en)
FR (1) FR12C0052I2 (en)
HK (1) HK1047545B (en)
HR (1) HRP20020189A2 (en)
HU (1) HU229150B1 (en)
IL (2) IL148159A0 (en)
LU (1) LU92204I2 (en)
MX (1) MXPA02001811A (en)
MY (1) MY125490A (en)
NO (2) NO330562B1 (en)
NZ (1) NZ517038A (en)
PL (1) PL211402B1 (en)
SI (1) SI1225881T1 (en)
TW (3) TWI367751B (en)
UA (1) UA75580C2 (en)
WO (1) WO2001017521A1 (en)
ZA (1) ZA200201407B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
EP1671628B1 (en) * 1999-09-03 2012-10-03 APBI Holdings, LLC Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
NZ528935A (en) 2001-03-16 2004-10-29 Dmi Biosciences Inc Method of delaying ejaculation
CZ20032644A3 (en) 2001-03-29 2004-06-16 Bristol-Myers Squibb Company Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
CA2410966C (en) * 2002-11-01 2005-11-22 Craig J. Hudson Sexual desire and performance enhancement with protein-bound tryptophan
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
GB0318706D0 (en) * 2003-08-08 2003-09-10 Pfizer Ltd Selective serotonin reuptake inhibitors in the treatment of disease
DE102009015702A1 (en) 2009-03-31 2010-10-07 Ratiopharm Gmbh Tablets containing dapoxetine and dry processing for their preparation
DE102009058321A1 (en) 2009-12-15 2011-06-16 Ratiopharm Gmbh Orodispersible tablet containing dapoxetine
JP2013530220A (en) 2010-07-06 2013-07-25 ナビファーム．カンパニー リミテッド Time-controlled sustained release oral administration pharmaceutical composition comprising dapoxetine
RU2463033C2 (en) * 2010-08-06 2012-10-10 Василий Федорович Пятин Method of treating premature ejaculation
CN103100085A (en) * 2011-11-09 2013-05-15 上海兰蒂斯生物医药科技有限公司 Pharmaceutical composition
CN103130660B (en) * 2011-11-25 2014-09-17 厦门福满药业有限公司 Acidic salt and crystal of dapoxetine and preparation method of crystal
WO2014042416A1 (en) * 2012-09-13 2014-03-20 주식회사 씨티씨바이오 Oral composition containing dapoxetin-free base
KR101432905B1 (en) 2012-12-11 2014-08-21 가톨릭대학교 산학협력단 Pharmaceutical composition for treating genetic pain comprising dapoxetine
US20160101093A1 (en) * 2013-05-21 2016-04-14 Jason B. Wynberg Methods for the treatment of premature ejaculation
CN103735525B (en) * 2014-02-12 2015-05-06 江苏仁寿药业有限公司 Dapoxetine tablets and preparation method thereof
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
WO2016025541A1 (en) * 2014-08-12 2016-02-18 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
WO2018102233A1 (en) * 2016-11-30 2018-06-07 Wang tian xin Therapeutical methods, formulations and nutraceutical formulations
TR201620151A2 (en) 2016-12-30 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING TADALAFIL AND DAPOXETIN
CN113143879A (en) * 2021-05-07 2021-07-23 苏州康恒研新药物技术有限公司 Preparation method of dapoxetine hydrochloride sustained release tablet
CN113181127A (en) * 2021-05-07 2021-07-30 苏州康恒研新药物技术有限公司 Preparation method of dapoxetine hydrochloride pellet tablets
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
US20250152523A1 (en) * 2023-11-09 2025-05-15 Woody's Medical LLC Compositions for treatment of sexual dysfunction

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4194009A (en) * 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4207343A (en) * 1978-06-22 1980-06-10 Eli Lilly And Company 1-Phenyl-3-(substituted phenoxy)propylamines
US4329356A (en) * 1980-10-31 1982-05-11 Eli Lilly And Company Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5135947A (en) * 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4866046A (en) 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5082667A (en) 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5589511A (en) 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5151448A (en) * 1991-07-12 1992-09-29 Crenshaw Roger T Method for treating premature ejaculation
US5151488A (en) * 1991-11-12 1992-09-29 The Mead Corporation Liquid crystal polymers containing a repeating bisoxazole structure
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5292962A (en) 1992-12-11 1994-03-08 Eli Lilly And Company Intermediates to 1-phenyl-3-naphthalenyloxy-propanamines
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
IT1264965B1 (en) 1993-11-12 1996-10-17 Giorgio Cavallini USE OF ALFA 1-BLOCCANTI IN THE TREATMENT OF EARLY EJACULATION
ATE312609T1 (en) 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc SUBLINGUAL COMPOSITION CONTAINING APOMORPHINE FOR THE DIAGNOSTICS OF FUNCTIONAL IMPOTENCY
CA2134038C (en) 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of a drug by a serotonin 1A receptor antagonist
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5627196A (en) 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
AU4918796A (en) 1995-02-10 1996-08-27 Eli Lilly And Company Methods of treating or preventing psychiatric disorders
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
HUP9802433A3 (en) 1995-10-13 2000-03-28 Neurosearch As 8-azabicyclo[3.2.1]oct-2-ene derivatives, their preparation and use
US5758911A (en) * 1996-02-07 1998-06-02 Northrop Grumman Corporation Linear motion wind driven power plant
US5897864A (en) 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5830500A (en) * 1996-07-22 1998-11-03 Pentech Pharmaceuticals, Inc. Low dose fluoxetine tablet
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5672612A (en) 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
CA2290969C (en) 1997-07-01 2004-02-17 Pfizer Products Inc. Delayed-release dosage forms of sertraline
IL133080A0 (en) 1997-07-01 2001-03-19 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
TR199903282T2 (en) 1997-07-01 2000-08-21 Pfizer Products Inc. Solution dosage form of sertraline encapsulated with gelatin.
FR2765483B1 (en) * 1997-07-04 2000-02-04 Philippe Gorny MEDICINE FOR TREATING ERECTILE DYSFUNCTIONS
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US6037360A (en) 1997-10-28 2000-03-14 Vivus, Incorporated Administration of 5-HT3 receptor antagonists to treat premature ejaculation
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
UA66370C2 (en) * 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
PA8469101A1 (en) 1998-04-09 2000-09-29 Pfizer Prod Inc AZABICICLIC LEAGUES OF RECEIVERS 5HT1
US6303627B1 (en) 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
WO1999065492A1 (en) 1998-06-19 1999-12-23 Eli Lilly And Company Inhibition of serotonin reuptake
FR2781671A1 (en) 1998-07-28 2000-02-04 Synthelabo PHARMACEUTICAL COMPOSITIONS CONTAINING SEROTONIN RECAPTURE INHIBITOR AND THERAPEUTIC USE THEREOF
US6150376A (en) 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
UA72743C2 (en) 1998-10-13 2005-04-15 Pfizer Prod Inc Essentially nonaqueous liquid pharmaceutical concentrate composition containing sertraline, method of using this concentrate, method for treatment
AU4982300A (en) * 1999-05-06 2000-11-21 Pentech Pharmaceuticals, Inc. Regimen and kit for amelioration of premature ejaculation
US20010003120A1 (en) * 1999-05-14 2001-06-07 M. D. Robert Hines Method for treating erectile dysfunction
EP1671628B1 (en) * 1999-09-03 2012-10-03 APBI Holdings, LLC Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction

Also Published As

Publication number Publication date
WO2001017521A1 (en) 2001-03-15
KR100719977B1 (en) 2007-05-21
NO20021035L (en) 2002-05-02
CN1387432A (en) 2002-12-25
TWI367751B (en) 2012-07-11
DK1225881T3 (en) 2006-06-12
KR20020025252A (en) 2002-04-03
EP1889614A2 (en) 2008-02-20
IL148159A0 (en) 2002-09-12
CA2383785A1 (en) 2001-03-15
IL148159A (en) 2009-11-18
CN1222283C (en) 2005-10-12
AU6891100A (en) 2001-04-10
EA004101B1 (en) 2003-12-25
HK1047545A1 (en) 2003-02-28
HRP20020189A2 (en) 2004-02-29
US20050261377A1 (en) 2005-11-24
LU92204I2 (en) 2013-07-23
DE122009000036I1 (en) 2009-11-05
MY125490A (en) 2006-08-30
HK1091418A1 (en) 2007-01-19
BR0014166A (en) 2002-05-14
HU229150B1 (en) 2013-09-30
CZ2002784A3 (en) 2002-09-11
EP1889614A3 (en) 2010-09-22
DE60026146T2 (en) 2006-08-17
JP2001089394A (en) 2001-04-03
DE122009000036I2 (en) 2010-05-06
ZA200201407B (en) 2003-07-30
US20140221497A1 (en) 2014-08-07
CY2012028I2 (en) 2017-04-05
SI1225881T1 (en) 2006-06-30
DE60026146D1 (en) 2006-04-27
TW200524582A (en) 2005-08-01
EP1671628B1 (en) 2012-10-03
CZ299712B6 (en) 2008-10-29
HUP0202687A3 (en) 2006-03-28
BG106461A (en) 2002-12-29
NZ517038A (en) 2003-04-29
FR12C0052I2 (en) 2013-08-16
CY2012028I1 (en) 2017-04-05
ES2393582T3 (en) 2012-12-26
NO2012015I2 (en) 2013-08-26
NO330562B1 (en) 2011-05-16
US7718705B1 (en) 2010-05-18
FR12C0052I1 (en) 2012-05-10
PL211402B1 (en) 2012-05-31
JP3194734B2 (en) 2001-08-06
MXPA02001811A (en) 2002-08-06
NO20021035D0 (en) 2002-03-01
CA2383785C (en) 2009-02-17
EP1225881B1 (en) 2006-02-22
EE05315B1 (en) 2010-08-16
NO2012015I1 (en) 2012-09-11
HK1047545B (en) 2006-09-22
TW201018459A (en) 2010-05-16
UA75580C2 (en) 2006-05-15
BG65677B1 (en) 2009-06-30
US20050215617A1 (en) 2005-09-29
ATE318135T1 (en) 2006-03-15
TWI312678B (en) 2009-08-01
EA200200324A1 (en) 2002-08-29
PL364924A1 (en) 2004-12-27
ES2256032T3 (en) 2006-07-16
EP1225881A1 (en) 2002-07-31
HUP0202687A2 (en) 2002-12-28
EE200200107A (en) 2003-04-15
AU762934B2 (en) 2003-07-10
EP1671628A1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
FR12C0052I1 (en)
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
ES2165990T3 (en) THIP FOR THE TREATMENT OF SLEEP DISORDERS.
BR0316753A (en) Treatment method for sexual dysfunction
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
PL366633A1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
ZA200109322B (en) A new use for deferiprone.
MXPA03004288A (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine.
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
PT1183046E (en) AMINOTETRALIN DERIVATIVES FOR THE THERAPY OF CARDIOVASCULAR DISEASES
CY1118068T1 (en) THE USE OF DOXOXETINE, A SPEED-LAUNCHED SELECTIVE OPTIONAL INHIBITOR FOR SEPOTONINE TREATMENT FOR THERAPEUTIC ADMINISTRATION
UA33498A (en) Method for treatment of resistant forms of schizophrenia
UY26405A1 (en) METHOD FOR TREATING PARKINSON&#39;S EVIL THROUGH THE ADMINISTRATION OF (-) - 5-CETO-2-N, N-D1-N-PROPYLAMINE-TETRAHYDROTETRALINE.
ECSP993026A (en) COMBINATION OF FENTOLAMINE AND APOMORPHINE FOR THE TREATMENT OF HUMAN SEXUAL FUNCTION AND DYSFUNCTION